Marketing for SaMD, imaging AI and clinical decision support, where one verb can change your regulatory regime and every claim gets checked.
Senior team, no juniors on your account, 30-day cancellation notice. Your first call is with a co-founder.
FDA's January 2026 clinical decision support guidance draws the device line partly by wording, so “predicts” versus “flags for review” is a legal decision, and marketing owns the wording.
The CMIO and the CIO ask different questions, and neither uses the product. 92% of health systems now review third-party AI before deployment; under half can validate it in-house.
The field taught them to: 44% of 224 funded digital health companies scored zero on published clinical evidence (JMIR, 2022). An unsourced accuracy number now reads as a warning sign.
In Kaiser Permanente's ambient AI rollout, 28% of 3,442 physicians passed 100 encounters in the first ten weeks. Sustained clinical use gets built after the contract, with the users.
We build the claim library from your regulatory file, attach substantiation to every sentence, and route drafts to your legal owner at outline stage. Review rounds shrink, campaigns ship inside the congress calendar, and nobody renegotiates the same sentence twice.
Europe's hospital market is countable and the US health-system list is finite, so demand generation is account-based by default: named accounts, role-specific messaging for CMIO and CIO, LinkedIn programs reported against the list rather than against clicks.
Specialty associations and congresses reach the clinicians who stay off LinkedIn deliberately. We plan the year around your two or three decisive meetings, with podium support, side events, and follow-up that turns badge scans into evaluations.
Co-authorship, case documentation and validation write-ups beat free pilots. We produce evidence content with your clinical team, structured so a governance committee can score it and an AI search engine can cite it.
Tracking pixels on health pages have produced over $100 million in settlements since 2023. We audit tags and consent before the first campaign, keep patient data out of marketing entirely, and build attribution on account signals instead.
Modest and substantiated beats impressive and retracted.
We don’t like to work from templates. Your Head of Growth builds the strategy around your product, your buyers and how hospitals evaluate clinical software. The cards below show one example for a healthtech company.
Buyer: CMIO, CIO, clinicians and the AI governance committee between them. Proof bar: published validation. Scope: SaMD, imaging AI, decision support, monitoring.
Physical devices and diagnostics hardware sold through procurement and value analysis committees. Proof bar: clinical data plus a per-procedure economic case.
Hospital software without clinical claims: interoperability, admin AI, scheduling, revenue cycle. Buyer: CIO and operations. Proof bar: returned staff capacity.
Practitioner interviews on hospital committees, clinician channels, the evidence bar for AI products and the compliance traps in health marketing. No form.
Amsterdam and New York, one team across GDPR and HIPAA markets, FDA and MDR regimes included.